Tandem won FDA clearance for a tubeless Mobi option that lets users choose between tubed and tubeless wear. The U.S. launch is planned for the first half of 2027, so sales gains have not happened yet; the added choice still makes this positive.
The new option could make Mobi work for more people who prefer not to wear tubing. It also keeps Control-IQ+ available. The product is not on sale yet, and Tandem names supply and manufacturing problems as risks.
Follow Tandem Diabetes Care, Inc. (TNDM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TNDM